Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market
businessinsider.com
finance
2022-10-17 07:00:00

New agreement adds two Telix investigational PET imaging radiotracers to GE Healthcare's immuno-diagnostic portfolio, to enable patient selection and monitoring in immunotherapy trialsTelix tracers evaluate levels of carbonic anhydrase IX and lactate in tumours to inform and improve therapy selectionGE Healthcare's Pharmaceutical Diagnostics business is an established global supplier of PET imaging tracers to the global clinical research marketMELBOURNE, Australia, Oct. 17, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has today announced a collaborative development and reseller agreement with GE Healthcare to supply its investigational positron emission tomography (PET) imaging radiotracers, TLX250-CDx (89Zr-DFO-girentuximab), and [18F]-FLac (18F-3-fluoro-2-hydroxypropionate) for use in third party clinical research and development activities.
